Clinical Oncology
Volume 19, Issue 8 , Pages 593-595 , October 2007

Improving Adjuvant Chemotherapy in Breast Cancer — Can We Get More for Less with TACT2?

  • L. Johnson

      Affiliations

    • Section of Clinical Trials, Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    • Corresponding Author InformationAuthor for correspondence: L. Johnson, Section of Clinical Trials, Sir Richard Doll Building, Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK.
    • ,
  • D. Cameron

      Affiliations

    • University of Leeds, Cookridge Hospital, Leeds L16 6QB, UK and Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
    • ,
  • P. Barrett-Lee

      Affiliations

    • Velindre Hospital, Whitchurch, Cardiff CF4 7XL, UK
    • ,
  • P. Canney

      Affiliations

    • Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, UK
    • ,
  • J.M. Bliss

      Affiliations

    • Section of Clinical Trials, Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    • ,
  • on behalf of the TACT2 Trial Management Group

Received 5 June 2007 ,Accepted 26 June 2007.

References 

  1. Early Breast Cancer Trialists' Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  2. Poole CJ, Earl H, Hiller L, et al. for the NEAT investigators and the SCTBG Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355:1851–1862
  3. Barrett-Lee P, Ellis P, Bliss J on behalf of the TACT Trial Management Group. Duration of adjuvant chemotherapy; anthracyclines, taxanes and novel agents — more or less. Clin Oncol. 2002;14:263–266
  4. Burnell M, Levine M, Chapman JA, et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of an interim analysis. San Antonio Breast Cancer Symposium 2006 (abstract 53).
  5. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004;22:2284–2293
  6. Stockler MR, Sourjina T, Harvey V, et al. A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. San Antonia Breast Cancer Symposium 2006 (abstract 6066).
  7. Wunderlich AK, Schmalenberg HS. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14:881–893
  8. Woll PJ, Thatcher N, Lomax L, et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. J Clin Oncol. 2001;19:712–719
  9. Huisman C, Biesma B, Postmus PE, et al. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. Br J Cancer. 2001;85:1456–1461
  10. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439
  11. Hudis C, Citron M, Berry D, et al. Five year follow-up of INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat. 2005;94:S51
  12. Fornier MN, Seidman AD, Lake D, et al. Increased dose-density (DD) is feasible: a pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10–11 day interval with filgrastim support, for women with early breast carcinoma (BC). J Clin Oncol. 2005;ASCO(23):(16S), 616
  13. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005;97(23):1724–1733
  14. Leonard RC, Miles D, Thomas R, et al. UK Breast Cancer Neutropenia Audit Group Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer. 2003;89(11):2062–2068
  15. Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003;10(3):715–724
  16. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524–4531
  17. The Adjuvant Breast Cancer Trials Collaborative Group . Polychemotherapy for early breast cancer: results from the International Adjuvant Breast Cancer Chemotherapy Randomized Trial. J Natl Cancer Inst. 2007;99(7):506–515
  18. The Adjuvant Breast Cancer Trials Collaborative Group . Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. J Natl Cancer Inst. 2007;99(7):516–525

PII: S0936-6555(07)00690-5

doi: 10.1016/j.clon.2007.06.016

Clinical Oncology
Volume 19, Issue 8 , Pages 593-595 , October 2007

Article Tools

* Image Usage & Resolution